{"id":41357,"date":"2024-07-03T12:29:04","date_gmt":"2024-07-03T12:29:04","guid":{"rendered":"https:\/\/ibima.eu\/estudio-intervencionista-de-extension-en-fase-iii-para-investigar-la-seguridad-y-la-tolerabilidad-a-largo-plazo-de-tolebrutinib-en-participantes-con-esclerosis-multiple-recidivante-esclerosis-multipl\/"},"modified":"2024-07-03T12:29:04","modified_gmt":"2024-07-03T12:29:04","slug":"estudio-intervencionista-de-extension-en-fase-iii-para-investigar-la-seguridad-y-la-tolerabilidad-a-largo-plazo-de-tolebrutinib-en-participantes-con-esclerosis-multiple-recidivante-esclerosis-multipl","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-intervencionista-de-extension-en-fase-iii-para-investigar-la-seguridad-y-la-tolerabilidad-a-largo-plazo-de-tolebrutinib-en-participantes-con-esclerosis-multiple-recidivante-esclerosis-multipl\/","title":{"rendered":"Estudio intervencionista de extensi\u00f3n en fase III para investigar la seguridad y la tolerabilidad a largo plazo de tolebrutinib en participantes con esclerosis m\u00faltiple recidivante, esclerosis m\u00faltiple primaria progresiva o esclerosis m\u00faltiple secundaria progresiva no recidivante"},"content":{"rendered":"
ANA MAR\u00cdA ALONSO TORRES – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – SANOFI AVENTIS RECHERCHE & DEVELOPPEMENT<\/p>","protected":false},"excerpt":{"rendered":"
ANA MAR\u00cdA ALONSO TORRES – ENSAYO CL\u00cdNICO CON MEDICAMENTOS – SANOFI AVENTIS RECHERCHE & DEVELOPPEMENT<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2283],"tags":[],"class_list":["post-41357","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-c-01-ensayos-clinicos"],"acf":[],"yoast_head":"\n